abstract |
This disclosure relates to compounds of formula (I) or a npharmaceutically acceptable salt thereof: n nin which m, p, A, Ar1, Ar2, Ar3, R1, R2, and R3 are defined in the nspecification. The compounds of formula (I) can be used as CGRP nantagonists and can be used to treat migraine. |